ArticleNeurocritical care2026
A Harmonised Protocol for the Use of PRx in Adult and Paediatric TBI Patients with ICP Monitoring: CLINICCA Workgroup Output.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA survey of 44 worldwide clinical experts in continuous monitoring of cerebral autoregulation (CCA) revealed that while half used a CCA index in clinical decision making, only 39% were using it as part of a local clinical protocol (CLINICCA survey, 2023). We aimed to distil common elements from existing protocols, focusing on the intracranial pressure (ICP) derived pressure reactivity index (PRx) in traumatic brain injury (TBI). METHODOLOGY: A template for a protocol followed the structure of the original CLINICCA survey which included five components: (1) PRx value triggering further clinical review, (2) PRx value informing approach to intracranial hypertension management, (3) derived CPP targets used to 'optimise' brain physiology, (4) derived CPP targets used to decrease the burden of therapy and (5) use of PRx and derived CPP targets in a stepwise approach within a multimodality protocol. Each component included four contingencies: 'what', 'when', 'advantages' and 'reservations'. Respondents using PRx and/or derived CPP targets in adult or paediatric TBI were invited to edit the template, submit local protocols, and provide clinical practice examples. Feedback was harmonised into a final protocol.
resultsContributors from nine centres edited the template, and two centres submitted written protocols. Most centres expanded components related to PRx status prompting clinical review and informing intracranial hypertension management. Variability existed in the use of derived CPP targets and neuromonitoring modalities incorporated into implementation of multimodality monitoring based practice. A supplement for technical advice regarding PRx use was created.
conclusionsCreating a harmonised protocol on the basis of common themes amongst currently used clinical protocols and approaches might facilitate broader implementation of CCA-guided therapy and inform future clinical trial design. Sharing protocols and identifying variability may promote discussion regarding advantages and limitations of PRx use in TBI.
Indexed as
Identifiers
42625004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.